1. Home
  2. CLBT vs NAMS Comparison

CLBT vs NAMS Comparison

Compare CLBT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellebrite DI Ltd.

CLBT

Cellebrite DI Ltd.

HOLD

Current Price

$12.72

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$33.21

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLBT
NAMS
Founded
1999
2019
Country
Israel
Netherlands
Employees
1285
100
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CLBT
NAMS
Price
$12.72
$33.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$22.50
$46.75
AVG Volume (30 Days)
1.8M
816.9K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$21.45
$17.96
Revenue Next Year
$17.47
$540.65
P/E Ratio
$45.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.03
$15.82
52 Week High
$20.53
$42.00

Technical Indicators

Market Signals
Indicator
CLBT
NAMS
Relative Strength Index (RSI) 45.11 52.76
Support Level $11.76 $29.73
Resistance Level $15.09 $37.43
Average True Range (ATR) 0.73 1.75
MACD -0.10 0.24
Stochastic Oscillator 47.80 57.94

Price Performance

Historical Comparison
CLBT
NAMS

About CLBT Cellebrite DI Ltd.

Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: